David Altarac
Chief Medical Officer of ISTDr. David Altarac, M.D., MPA is Chief Medical Officer of Innoviva Specialty Therapeutics at Innoviva, Inc. from February 2024. He serves as Chief Medical Officer of IST at Innoviva Inc. from May 2025. Dr. Altarac is an infectious disease physician and accomplished pharmaceutical executive with extensive experience leading clinical and regulatory functions at several leading biotechnology and pharmaceutical companies. Dr. Altarac previously served as the Chief Medical Officer of Innoviva Specialty Therapeutics following the 2023 acquisition of Entasis Therapeutics where he was Chief Medical Officer. Dr. Altarac serves as Chief Medical Officer of Entasis Therapeutics Holdings Inc. November 4, 2019. He was Senior Vice President and Head of Global Regulatory Affairs, Global Drug Safety and R&D Quality and Compliance at Shire from July 2015 to April 2019. He served as Vice President of Regulatory Affairs at Neostem, Inc. since July 2013 to June 2015. Dr. Altarac joined Neostem executive management team in December 2013. He has an impressive resume of experience in U.S. and global regulatory affairs, operations, labeling and organizational design. He served for many years at Merck and Company, Inc. from 2011-2013, where he served as Vice President of Regulatory Affairs Emerging Markets R & D at Merck Research Labs. He was responsible for overseeing the regulatory affairs (operations and strategy) for Merck’s Emerging Markets (EM) group, which includes Brazil, Russia, India, China, Korea, Turkey and Mexico. He also worked to develop robust interfaces with regulatory support teams throughout Merck’s business units including Worldwide Product Labeling, Global Regulatory Operations, Global Safety and Merck Enterprise groups including Global Human Health, Merck Manufacturing Division, Merck Consumer Care and Merck Vaccines Division. At Merck, Dr. Altarac served as Vice President of Worldwide Regulatory Group 2 from 2009 to 2011 and was responsible for all regulatory affairs, strategic activities for the bone, respiratory, inflammation, endocrine, oncology, neurosciences, ophthalmology, women’s health franchises and programs in gastrointestinal, anemia and urology. He also led the Worldwide Product Labeling Organization and was responsible for developing and maintaining all Merck product labels for drugs, biologics and vaccines. Dr. Altarac was a Senior Representative of Merck and was a key Member of the global regulatory affairs leadership team. From 2008 to 2009, he served as an Executive Director-Vice President of Worldwide Regulatory Group 1, where he was responsible for the worldwide regulatory affairs in the bone, respiratory and oncology franchises and the gastrointestinal, inflammation, anemia and urology programs. In addition, Dr. Altarac served as Worldwide Regulatory Lead in the Asia Pacific region and Interim Acting Head of Worldwide Product Labeling. Dr. Altarac received his M.D. from New York Medical College. He completed his medical training in Internal Medicine and Infectious Diseases at Beth Israel Medical Center in New York. He holds a Master of Public Administration (M.P.A) from New York University and a B.A. in Chemistry from SUNY Binghamton (State University of New York at Binghamton).
Positions
- Company NameInnoviva, Inc.Stock CodeINVAPositionChief Medical Officer of ISTColleagues
- PRPavel RaifeldCEO & Director
- SBStephen BassoChief Financial Officer
- MZMarianne ZhenChief Accounting Officer & Secretary
- PMPatricia M. DrakeChief Commercial Officer-Innoviva Specialty Therapeutics, Inc.
- JAJules A. HaimovitzIndependent Director
- SJSarah J. SchlesingerIndependent Director
- JLJosephine LindenIndependent Director
